{"doi":"10.1016/j.ijid.2025.107983","title":"Comparable effectiveness of MF59®-adjuvanted and high-dose quadrivalent inactivated influenza vaccines for prevention of test-confirmed influenza during the 2022-2023 influenza season","abstract":null,"journal":"International Journal of Infectious Diseases","year":2025,"id":654825,"datarank":0.29188652235829704,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.0,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":876135,"name":"Benjamin Chastek","orcid":"0000-0002-9759-6001","position":1,"is_corresponding":false},{"id":1665436,"name":"Tim Bancroft","orcid":null,"position":2,"is_corresponding":false},{"id":1709049,"name":"Noah Webb","orcid":null,"position":3,"is_corresponding":false},{"id":936282,"name":"Stephen I. Pelton","orcid":"0000-0003-4862-5344","position":4,"is_corresponding":false},{"id":1709050,"name":"Mendel D.M. Haag","orcid":null,"position":5,"is_corresponding":false},{"id":1709051,"name":"Ian McGovern","orcid":null,"position":6,"is_corresponding":false},{"id":2045,"name":"Mahrukh Imran","orcid":"0000-0002-2478-0182","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Comparable effectiveness of MF59®-adjuvanted and high-dose quadrivalent inactivated influenza vaccines for prevention of test-confirmed influenza during the 2022-2023 influenza season","abstract":"OBJECTIVE: Adjuvanted and higher-dose influenza vaccines are recommended by the US Advisory Committee on Immunization Practices (ACIP) for adults ≥65 years. This study estimated the relative vaccine effectiveness (rVE) of adjuvanted quadrivalent influenza vaccine (aQIV) versus high-dose QIV (HD-QIV) in preventing test-confirmed influenza in US adults ≥65 years during the 2022-2023 season. METHODS: In a retrospective test-negative design, electronic health records and claims data from the Optum Market Clarity database were used to identify adults ≥65 years who received aQIV or HD-QIV and were tested for influenza associated with acute respiratory or febrile illness in any setting or during emergency department visits or inpatient admissions (ED/inpatient). A doubly robust model was used, combining inverse probability of treatment weighting and logistic regression. RESULTS: Of 4,228,481 adults ≥65 years who received aQIV or HD-QIV, 30,911 were tested for influenza and met selection criteria (2361 cases; 28,550 controls). The rVE of aQIV vs HD-QIV was -2.5% (95% CI, -13.4% to 7.4%) in any setting and 0.0% (95% CI, -15.9% to 13.7%) in ED/inpatient settings. CONCLUSION: Similar to previous studies, aQIV and HD-QIV provided comparable protection against test-confirmed influenza in any setting, including ED/inpatient, aligning with ACIP and other recommendations for adults ≥65 years.","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40659177","pmcid":null,"openalex_id":"https://openalex.org/W4412432509","authors":[],"funders":[{"funder_name":"CSL Seqirus Australia","grant_id":"","title":null}],"total_grants":1,"fwci":3.6452,"citation_percentile":0.93528498,"influential_citations":0,"citation_trend":[{"year":2026,"count":5}],"oa_status":"gold","license":"cc-by-sa","oa_locations":[{"url":"https://www.ijidonline.com/article/S1201-9712(25)00207-3/pdf","host_type":"journal"},{"url":"https://www.ijidonline.com/article/S1201-9712(25)00207-3/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1201971225002073?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1201971225002073?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.ijid.2025.107983","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40659177","host_type":"repository"},{"url":"https://doaj.org/article/c1ef188a6ea04abe951248d91634d485","host_type":"repository"}],"fields_of_study":["Influenza Virus Research Studies","Respiratory viral infections research","Pharmacovigilance and Adverse Drug Reactions"],"mesh_terms":["Vaccine Efficacy","Adjuvants, Immunologic","Aged","Aged, 80 and over","Female","Humans","Influenza, Human","Influenza Vaccines","Male","Polysorbates","Retrospective Studies","Seasons","Squalene","United States","Vaccines, Inactivated"],"keywords":["Medicine","Virology","Influenza season","Seasonal influenza","Influenza vaccine","Immunology","Internal medicine","Vaccination","Coronavirus disease 2019 (COVID-19)","Real-world Data","High-dose Influenza Vaccine","Test-negative Design","Adjuvanted Influenza Vaccine","Test-confirmed Influenza, Laboratory-confirmed Influenza","Older Adults Aged ≥65 Years"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T08:34:26.993917Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}